Abstract 3890: HDAC6 as a convergent oncogenic and immunoregulatory hub across multiple cancer types.

Abstract Histone deacetylase 6 (HDAC6) has emerged as a critical regulator of tumor progression across multiple malignancies. Our integrated analyses reveal that environmental phthalates (BBP, DBP) drive oncogenic processes in breast epithelial stem cells and ER-negative breast cancer by activating ER-EGFR-PKA or AhR-cAMP-PKA-CREB1 signaling, leading to HDAC6 upregulation, β-catenin/LEF1-TCF4 activation, epithelial-mesenchymal transition (EMT), and enhanced metastatic potential. Beyond breast cancer, clinical datasets and functional studies demonstrate that elevated HDAC6 expression correlates with advanced stage, higher tumor grade, and poor survival in lung cancer, oral squamous cell carcinoma (OSCC), and endometriosis-associated ovarian carcinoma (EAOC). Mechanistically, HDAC6 promotes tumor progression by regulating HIF-1α/BNIP3-mediated autophagy in lung cancer, driving AP-1-dependent IL-13 expression and M2 macrophage polarization in OSCC, and mediating ARID1A mutation-associated IL-10-driven immunosuppressive macrophage programming in EAOC. Importantly, pharmacologic HDAC inhibition (TSA, vorinostat) suppresses autophagy, reverses macrophage polarization, reduces EMT, and markedly inhibits tumor growth in relevant in vitro and in vivo models. Together, these findings position HDAC6 as a convergent oncogenic and immunoregulatory hub across environmentally induced, hormone-independent, and mutation-associated cancers, supporting HDAC6-targeted therapies as a promising strategy for limiting tumor progression and reshaping the tumor immune microenvironment. Citation Format: Chia-Wei Wu, Chia-Yi Hsu, Eing-Mei Tsai, Tsung-Hua Hsieh. HDAC6 as a convergent oncogenic and immunoregulatory hub across multiple cancer types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3890.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-3890
Primary Topic
Histone Deacetylase Inhibitors Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 3890: HDAC6 as a convergent oncogenic and immunoregulatory hub across multiple cancer types.

Tsung-Hua Hsieh, Chia‐Wei Wu, Eing-Mei Tsai, Chia-Yi Hsu
Cancer Research
Histone Deacetylase Inhibitors Research
article

Abstract 3890: HDAC6 as a convergent oncogenic and immunoregulatory hub across multiple cancer types.

Tsung-Hua Hsieh, Chia‐Wei Wu, Eing-Mei Tsai, Chia-Yi Hsu
article en

Abstract

Abstract Histone deacetylase 6 (HDAC6) has emerged as a critical regulator of tumor progression across multiple malignancies. Our integrated analyses reveal that environmental phthalates (BBP, DBP) drive oncogenic processes in breast epithelial stem cells and ER-negative breast cancer by activating ER-EGFR-PKA or AhR-cAMP-PKA-CREB1 signaling, leading to HDAC6 upregulation, β-catenin/LEF1-TCF4 activation, epithelial-mesenchymal transition (EMT), and enhanced metastatic potential. Beyond breast cancer, clinical datasets and functional studies demonstrate that elevated HDAC6 expression correlates with advanced stage, higher tumor grade, and poor survival in lung cancer, oral squamous cell carcinoma (OSCC), and endometriosis-associated ovarian carcinoma (EAOC). Mechanistically, HDAC6 promotes tumor progression by regulating HIF-1α/BNIP3-mediated autophagy in lung cancer, driving AP-1-dependent IL-13 expression and M2 macrophage polarization in OSCC, and mediating ARID1A mutation-associated IL-10-driven immunosuppressive macrophage programming in EAOC. Importantly, pharmacologic HDAC inhibition (TSA, vorinostat) suppresses autophagy, reverses macrophage polarization, reduces EMT, and markedly inhibits tumor growth in relevant in vitro and in vivo models. Together, these findings position HDAC6 as a convergent oncogenic and immunoregulatory hub across environmentally induced, hormone-independent, and mutation-associated cancers, supporting HDAC6-targeted therapies as a promising strategy for limiting tumor progression and reshaping the tumor immune microenvironment. Citation Format: Chia-Wei Wu, Chia-Yi Hsu, Eing-Mei Tsai, Tsung-Hua Hsieh. HDAC6 as a convergent oncogenic and immunoregulatory hub across multiple cancer types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3890.

Cancer ResearchVol. 86(7_Supplement)
Kaohsiung Medical University (TW), Kaohsiung Medical University Chung-Ho Memorial Hospital (TW), E-Da Hospital (TW), I-Shou University (TW)
Openalex Percentile: Top 7%
Histone Deacetylase Inhibitors Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.